Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107411 | 0.81 | SMN1; SMN2 (0.43) | KDM4ETSHRPOLBSMN1; SMN2TP53 | |
| SCHEMBL7872706 | 0.72 | POLB (0.41) | KDM4ETSHRPOLBMEN1KMT2A | |
| SCHEMBL1107406 | 0.72 | MAPT (0.39) | KDM4EHCAR2TSHRSMN1; SMN2MEN1 | |
| SCHEMBL13771831 | 0.71 | PPARD (0.38) | KDM4EHCAR2TSHRSMN1; SMN2MEN1 | |
| SCHEMBL2668962 | 0.69 | CCNE1 (0.41) | — | |
| SCHEMBL972839 | 0.68 | MEN1 (0.33) | KDM4ETSHRPOLBMEN1KMT2A | |
| SCHEMBL2656358 | 0.66 | SMN1; SMN2 (0.42) | KDM4ETSHRPOLBSMN1; SMN2TP53 | |
| SCHEMBL9891665 | 0.66 | SMN1; SMN2 (0.36) | KDM4EHCAR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12574394 | 0.66 | KDM4E (0.39) | KDM4ETSHRPOLBMEN1KMT2A | |
| SCHEMBL28786616 | 0.66 | POLB (0.36) | TSHRPOLBMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | KDM4E 2516/4885HCAR2 477/4885TSHR 1677/4885 |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | KDM4E 2426/4885HCAR2 3588/4885TSHR 787/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | KDM4E 2516/4885HCAR2 477/4885TSHR 1677/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | KDM4E 2019/4885HCAR2 3182/4885TSHR 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.